CyTuVax   Report issue

For profit Phase 2
Founded: Maastricht Netherlands (2012)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2015
NCT02540538
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

CyTuVax

Active Ingredients

Drugs in Phase 2 Trials (2)

hbai20 (2 trials)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2